PepGen (PEPG) Stock Price, News & Analysis

Company Overview

PepGen Inc. is a clinical-stage biotechnology company developing genetic medicines for serious neuromuscular diseases. The company’s technology is designed to improve the delivery of oligonucleotide therapeutics into skeletal and cardiac muscle, with the goal of addressing diseases caused by genetic mutations or abnormal RNA processing.

PepGen’s platform, known as Enhanced Delivery Oligonucleotides (EDO), combines therapeutic oligonucleotides with proprietary peptides intended to facilitate their distribution into muscle tissue. The company’s research and development efforts have focused primarily on Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1).

Its lead programs include PGN-EDO51, an exon-skipping therapy being developed for a subset of patients with DMD who may benefit from exon 51 skipping, and PGN-EDODM1, an investigational treatment designed to address the underlying RNA-processing defects associated with DM1. PepGen is based in the United States and is advancing these programs through clinical development. James McNally serves as the company’s president and chief executive officer.

Key Stats

• Today's Range: $2.44 to $2.80
• 50-Day Range: $2.21 to $3.42
• 52-Week Range: $1.31 to $7.80
• Volume: 1.16 million shs
• Average Volume: 1.05 million shs
• Market Capitalization: $174.54 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.40
• Consensus Rating: Moderate Buy

PepGen Stock Analysis - MarketRank™

PepGen scored higher than 33% of companies evaluated by MarketBeat, and ranked 734th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

PepGen has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

PepGen has a consensus price target of $11.40, representing about 352.4% upside from its current price of $2.52.

Amount of Analyst Coverage

PepGen has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for PepGen are expected to decrease in the coming year, from ($1.11) to ($1.27) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of PepGen is -1.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of PepGen is -1.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

PepGen has a P/B Ratio of 1.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.18% of the float of PepGen has been sold short.

Short Interest Ratio / Days to Cover

PepGen has a short interest ratio ("days to cover") of 4.77.

Change versus previous month

Short interest in PepGen has recently increased by 9.15%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

PepGen does not currently pay a dividend.

Dividend Growth

PepGen does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, PepGen insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.30% of the stock of PepGen is held by insiders.

Percentage Held by Institutions

58.01% of the stock of PepGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/24/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:PEPG
• CIK: 1835597
• Web: www.pepgen.com
• Phone: 781-797-0979
• Fax: N/A
• Employees: 57
• Year Founded: 2018

Price Target and Rating

• Average Price Target for PepGen: $11.40
• High Price Target: $20.00
• Low Price Target: $4.00
• Potential Upside/Downside: +352.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.31)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$89.65 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -51.01%
• Return on Assets: -43.49%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.36
• Quick Ratio: 13.36

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.14 per share
• Price / Book: 1.18

Miscellaneous

• Outstanding Shares: 69,260,000
• Free Float: 68,360,000
• Market Cap: $174.54 million
• Optionable: Optionable
• Beta: 2.01